For research use only. Not for therapeutic Use.
Fianlimab（Cat No.:I042104）is an investigational monoclonal antibody that targets and inhibits the PD-1 receptor, a checkpoint protein on immune cells that can suppress immune responses. By blocking PD-1, Fianlimab aims to enhance the body’s immune system, allowing T-cells to effectively recognize and attack cancer cells. It is being studied in clinical trials for various cancers, including melanoma, non-small cell lung cancer, and head and neck cancer. Fianlimab is being evaluated for its potential to improve anti-tumor immunity, and ongoing research is focusing on its safety and efficacy as a cancer treatment.
| Catalog Number | I042104 |
| CAS Number | 2126132-98-5 |
| Purity | ≥95% |
